Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

- 1 min read

ZimVie Inc. Makes Strategic Move: Sells Spine Business to H.I.G. Capital for $375M

Westminster, CO, December 18, 2023 (Globe Newswire) -- ZimVie Inc. (Nasdaq: ZIMV), the 2022 spin-off of the dental and spine business units of Zimmer Biomet, made waves today by finalizing a deal to sell its spine business to H.I.G. Capital, a major player in the alternative investment scene. Vafa Jamali, President and CEO notes that this allows ZimVie to focus on the global dental markets.

Read full article here.

Recent Posts

See All

Weight-Loss Drug Startup Metsera Launches with $290M Funding

NY, NY, April 18, 2024 (Business Wire) -- Metsera, Inc., a pioneering player in the clinical-stage biopharmaceutical realm focusing on innovative treatments for obesity and metabolic ailments, has e

Flare Therapeutics Names Dr. Douglas Manion as New CEO

Cambridge, MA, April 23 2024 (PRNewswire) -- Flare Therapeutics Inc. has undergone a notable leadership transition with the selection of Dr. Douglas Manion, M.D., FRCP (C), as its newly appointed Ch

Incyte Corp. to Acquire Escient Pharmaceuticals for $750M

Wilmington, DE, April 23, 2024 (RTTNews) -- Incyte Corp. (INCY) is buying Escient Pharmaceuticals and its assets for $750 million, plus any cash left over when the deal closes. This acquisition need

Weight-Loss Drug Startup Metsera Launches with $290M Funding

Flare Therapeutics Names Dr. Douglas Manion as New CEO

Incyte Corp. to Acquire Escient Pharmaceuticals for $750M

Biopharmaceutical Leader Thomas Smart Takes Helm as CEO at Actym Therapeutics

Steris Sells Dental Segment to Peak Rock affiliate in $787M Deal

Alterome Therapeutics Raises $132M Led by Goldman Sachs for Precision Oncology Initiatives

Zura Bio Announces Robert Lisicki as CEO and Director

Obsidian Therapeutics Secures $160.5M Series C Funding for Advancement of OBX-115 Clinical Trials

Wolfgang Wienand Named New CEO of Lonza

J&J buys Shockwave for $13.1B

Executive Spotlights

ZimVie Inc. Makes Strategic Move: Sells Spine Business to H.I.G. Capital for $375M

Recent Posts

Life Science Headlines